Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it has successfully completed research and development on its program to produce ursodeoxycholic acid (UDCA), an active pharmaceutical ingredient (API) used in nutraceutical and pharmaceutical products.
"Our proprietary BioOxi platform on which we are commercially focused along with our stellar R&D team continues to showcase Willow's ability to leverage breakthrough technology to disrupt the status quo in producing key ingredients for large global markets," Dr. Chris Savile, Willow's president and CEO, said in a statement.
"As the next step, we look forward toward continuing our rewarding partnership with Sandhill by advancing production of UDCA and continuing to demonstrate Willow's ability to help partners to innovate manufacturing of important APIs and other ingredients."
The company noted that UDCA has applications as a medication for the management and treatment of cholestatic liver disease and gallstone conditions, and as an intermediate for the production of tauroursodeoxycholic acid.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage, and personal care markets.